H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
出版年份 2017 全文链接
标题
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-08-02
DOI
10.1038/s41598-017-07617-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- A Phase II study of olaparib in breast cancer patients: biological evaluation from a ‘window of opportunity’ trial
- (2016) Giandomenico Roviello et al. Future Oncology
- Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer
- (2016) Marta Truffi et al. PHARMACOLOGICAL RESEARCH
- PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells
- (2016) Shuhei Ito et al. PLoS One
- A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
- (2016) Philip C. Schouten et al. Trials
- Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and “BRCAness” Mutations
- (2016) Sanghee Hong et al. Journal of Oncology Practice
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
- (2015) William Jacot et al. Future Oncology
- Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity
- (2015) Joseph M. Caster et al. Nanoscale
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
- (2015) Fanny Le Du et al. Oncotarget
- BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
- (2015) Robin Dufour et al. Scientific Reports
- H-Chain Ferritin: A Natural Nuclei Targeting and Bioactive Delivery Nanovector
- (2015) Lianbing Zhang et al. Advanced Healthcare Materials
- The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
- (2014) Lisa A. Newman et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting homologous recombination-mediated DNA repair in cancer
- (2014) João FS Carvalho et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells
- (2014) Michela Bellini et al. JOURNAL OF CONTROLLED RELEASE
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors
- (2013) Zipeng Zhen et al. ACS Nano
- Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?
- (2013) Roxana Chiorean et al. BREAST
- IRP2 Regulates Breast Tumor Growth
- (2013) Wei Wang et al. CANCER RESEARCH
- Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
- (2013) Nigel Bundred et al. INVESTIGATIONAL NEW DRUGS
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
- (2012) Hsiao-Ching Chuang et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1
- (2012) N. Singh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- (2011) Tracy R. Daniels et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints
- (2010) Conly L. Rieder CHROMOSOME RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Management of breast cancer with targeted agents: importance of heterogenicity
- (2010) Serena Di Cosimo et al. Nature Reviews Clinical Oncology
- Binding and uptake of H-ferritin are mediated by human transferrin receptor-1
- (2010) Li Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein-Based Nanomedicine Platforms for Drug Delivery
- (2009) Aihui MaHam et al. Small
- Pharmacokinetics and Biodistribution of Nanoparticles
- (2008) Shyh-Dar Li et al. MOLECULAR PHARMACEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More